AN 2718

Drug Profile

AN 2718

Alternative Names: AN-2718

Latest Information Update: 13 Oct 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Anacor Pharmaceuticals
  • Class Antifungals; Organic boron compounds; Small molecules
  • Mechanism of Action Leucyl-tRNA synthetase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Candidiasis; Mycoses; Onychomycosis; Tinea

Most Recent Events

  • 13 Oct 2015 Discontinued - Phase-I for Tinea, Onychomycosis and Mycoses in USA before October 2015 (Topical)
  • 21 Mar 2013 AN 2718 is still in phase I development for Onychomyosis and other Mycoses in USA
  • 05 Mar 2009 Adverse events data from a phase I trial in Tinea released by Anacor Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top